Published in final edited form as:

Pancreas. 2010 May ; 39(4): 425–435. doi:10.1097/MPA.0b013e3181c15963.

Phenotype and Genotype of Pancreatic Cancer Cell Lines

Emily L. Deer, MD,

Department of Surgery, University of Utah School of Medicine, Salt Lake City, Utah

Jessica Gonzalez-Hernandez, BS,

Department of Surgery, University of Utah School of Medicine, Salt Lake City, Utah

Jill D. Coursen, MS,

Department of Surgery, University of Utah School of Medicine, Salt Lake City, Utah

Jill E. Shea, PhD,

Department of Surgery, University of Utah School of Medicine, Salt Lake City, Utah

Josephat Ngatia, MD,

Department of Surgery, University of Utah School of Medicine, Salt Lake City, Utah

Courtney L. Scaife, MD,

Department of Surgery, University of Utah School of Medicine, Salt Lake City, Utah

Matthew A. Firpo, PhD, and

Department of Surgery, University of Utah School of Medicine, Salt Lake City, Utah

Sean J. Mulvihill, MD

Department of Surgery, University of Utah School of Medicine, Salt Lake City, Utah

Abstract

The dismal prognosis of pancreatic adenocarcinoma (PA) is due in part due to a lack of molecular information regarding disease development. Established cell lines remain a useful tool for investigating these molecular events. Here we present a review of available information on commonly used PA cell lines as a resource to help investigators select the cell lines most appropriate for their particular research needs. Information on clinical history, in vitro and in vivo growth characteristics, phenotypic characteristics, such as adhesion, invasion, migration and tumorigenesis, and genotypic status of commonly altered genes (KRAS, p53, p16, and SMAD4) was evaluated. Identification of both consensus and discrepant information in the literature suggests careful evaluation before selection of cell lines and attention be given to cell line authentication.

Keywords

adhesion; angiogenic potential; invasion; migration; pancreatic adenocarcinoma cell lines; tumorigenicity

Correspondence: Matthew A. Firpo, PhD, 30 N 1900 E, Salt Lake City, Utah 84132, 801-587-9049, 801-581-6612 (fax), matt.firpo@hsc.utah.edu.

Current Address: Jessica Gonzalez-Hernandez, BS, University of Puerto Rico at Medical Sciences Campus, San Juan, Puerto Rico
Current Address: Josephat Ngatia, MD, Department of Anesthesiology, University of Florida, Gainesville, Florida

INTRODUCTION

Pancreatic adenocarcinoma (PA) is an aggressive disease that develops in a relatively symptom-free manner and is usually advanced at the time of diagnosis. As is common in epithelial tumors, carcinogenesis develops through accumulation of mutations and genetic lesions leading to activation of oncogenes and inactivation of tumor suppressor genes. Since multiple combinations of mutations can lead to the development of PA¹, disease sub-classes may present different survival strategies requiring multiple targeted intervention strategies. A thorough understanding of the specific cellular and molecular mechanisms of PA development and progression is required in order to identify early detection strategies, preventative measures, and effective interventions.

Both *in vitro* and *in vivo* experimentation involving cancer cell lines remains a convenient starting point for discovery and proof-of-concept studies. Investigations in colon and breast cancer indicate that cell lines recapitulate the genomic events leading to neoplastic changes seen in patient samples^{2, 3}. It is likely that a similar situation occurs in PA, which is supported by the fact that the four most common mutations occurring in PA tumors are found in cell lines at similar percentages (see below) and PA cell lines demonstrate disparate phenotypes and genotypes that are representative of PA sub-classes. This diversity facilitates mechanistic inferences and aids in proving causality through gain- and loss-of-function experiments. Examples of studies that capitalized on phenotypic differences in PA cell lines have provided mechanistic insight through linkage of differential expression of specific proteins to tumor growth, invasion and metastasis^{4, 5} and chemotherapeutic drug resistance⁶. Choosing cell lines for specific phenotypic characteristics is challenging due to the lack of comprehensive comparative studies. Furthermore, there are many apparent contradictory reports concerning both phenotype and genotype of PA cell lines. Here we present a review of the current information characterizing the eleven most commonly referenced pancreas cancer cell lines. Our goal was to identify consensus in the literature regarding phenotype and genotype as well as provide a compendium of PA cell line information that can be used as a reference and starting point for researchers.

CLINICAL PICTURE AND CELL LINE DERIVATION

Information concerning the clinical course of the donor patient and the site of derivation are important in defining the biologic and pathologic characteristics of the tumor cell line and should be considered in designing *in vitro* experiments. General characteristic of the donor subject, disease course, and cell line as well as the relevant references describing the original cell line derivation are shown in Table 1. More extensive descriptions of the histological appearance and differentiation of the tumor cell lines are summarized below. All donor patients were Caucasian between the ages of 26–65.

AsPC-1 was obtained from a 62-year-old woman with adenocarcinoma of the head of the pancreas and metastases to several abdominal organs. The patient received radiation and chemotherapy but eventually developed ascites and died two weeks later. The ascitic cell culture was noted to produce abundant mucin as well as carcinoembryonic antigen⁷.

BxPC-3 was cultured from a 61-year-old woman's adenocarcinoma of the body of the pancreas. The patient died 6 months later despite radiation and chemotherapy. No evidence of metastasis was found. Tumors grown in nude mice resemble the primary tumor of the patient and produced carcinoembryonic antigen, human pancreas cancer-associated antigen, human pancreas-specific antigen, and traces of mucin⁸.

Capan-1 was obtained from a liver metastasis of a 40-year-old male with a pancreas adenocarcinoma in the head of the pancreas. Metastases were present in regional lymph

nodes. In athymic mice, Capan-1 derived tumor produced mucin and was morphologically and biochemically similar to the tumor of origin⁹. Although not reported in the original publication, a doubling time of 41 hours was subsequently determined for Capan-1¹⁰.

Capan-2 originated from a 56-year-old male with pancreatic adenocarcinoma. The primary tumor involved the head of the pancreas and infiltrated the duodenal wall distal to the ampulla. The patient underwent pancreatectomy, cholecystectomy, partial gastrectomy, large and small bowel omentectomy and splenectomy. The patient received postoperative chemotherapy and died 6.75 years later¹¹.

CFPAC-1 was obtained from a liver metastasis of a 26-year old male with cystic fibrosis. Laparotomy revealed a well-differentiated adenocarcinoma in the head of the pancreas and multiple liver metastases¹². Carriers of mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (*CFTR*) commonly exhibit an idiopathic pancreatitis, which is a risk factor for pancreas cancer. In addition, it has been proposed that *CFTR* carrier status is a direct risk factor for young onset (before age 60) pancreas cancer¹³. On the contrary, other reports suggest there is no connection between cystic fibrosis and pancreas cancer^{14, 15}. Exactly what role, if any, *CFTR* carrier status plays in the pathogenesis of pancreas cancer remains unresolved. It is likely that the CFPAC-1 pancreas cancer cell line may have resulted from unique molecular events that may not be representative of the basic pathogenesis which characterizes the majority of pancreas cancer cases.

HPAC was derived from an adenocarcinoma found in the head of the pancreas in a 64-year-old female. The tumor was histologically described as moderately well-differentiated and of ductal origin¹⁶.

HPAF-II was obtained from the ascites of a 44-year-old male with pancreas adenocarcinoma and metastases to the liver, diaphragm and lymph nodes¹⁷.

Hs 766T was derived from the lymph node metastasis of a 64-year-old male with pancreas carcinoma^{18, 19}.

MIA PaCa-2 was derived from the pancreas adenocarcinoma of a 65-year-old man who presented with abdominal pain for 6 months and a palpable upper abdominal mass. The tumor involved the body and tail of the pancreas and had infiltrated the periaortic area. The tumor did not express measurable amounts of carcinoembryonic antigen and an alkaline phosphatase stain was negative²⁰.

PANC-1 was cultured from a 56-year-old male with an adenocarcinoma in the head of the pancreas which invaded the duodenal wall. Metastases in one peripancreatic lymph node were discovered during a pancreaticoduodenectomy. In culture, the cell line was not found to secrete significant carcinoembryonic antigen²¹.

SU.86.86 was obtained from a 57-year-old woman with an adenocarcinoma of the head of the pancreas. There was extensive metastasis to the liver and the tumor specimen was obtained from a liver metastasis. Histological evaluation showed a moderate-to-poorly differentiated adenocarcinoma²².

Table 1 lists doubling times as reported in the publication that originally described the cell line. Since differences in proliferation rates may arise due to variations in culture conditions, these doubling times might best be used as a relative guide. Subsequent studies report substantial differences from the original publications. For example, McIntyre and Kim

report doubling times of 26 hours for MIA PaCa-2 and 28 hours for PANC-1, whereas the original doubling times were reported as 40 and 52 hours respectively ¹⁰.

PHENOTYPE

For this review we focused on commonly used experimental systems involving PA cell line behavior in tissue culture and mouse xenograft models (adhesion, migration, invasion, angiogenic potential, and tumorigenicity). Our goal was to identify consensus differences in studies that compared multiple cell lines. Many of the studies were qualitative for which we report relative phenotypic differences. Where possible, we report quantitative, statistically significant differences.

Adhesion

The high metastatic potential of pancreas cancer underscores the importance of understanding the properties of cancer cell adhesion, which influences tumor growth and largely determines metastatic potential. Cell adhesion is mediated by the interaction of extracellular matrix components with cell-surface molecules. Many of the studies in pancreas cancer have focused on alterations in adhesive properties by the addition of cytokines or anti-cancer drugs in tissue culture, although several studies document adhesion to various substrates in two or more PA cell lines allowing the comparison of relative affinities (Table 2). Commonly studied extracellular matrix components mediating cell attachment were fibronectin, a glycoprotein found in basement membranes and connective tissues, collagens I and IV, found in tissue stroma and basement membranes, respectively ²³, and laminin, the main noncollagenous glycoprotein in the basement membrane ²⁴.

Agreement among reports of adhesive propensities exists for several cell lines. Specifically, Capan-1 bound more avidly to type I collagen compared with MIA PaCa-2 ^{10, 25–28}. Additionally, BxPC-3 and PANC-1 appeared to bind with equivalent affinity to type I collagen ^{25, 29, 30}. However, consensus in binding affinity with one medium does not necessarily translate to other types of binding material. For example, when Capan-1 and MIA PaCa-2 were plated on laminin, several groups observed equivalent binding affinity and one group reported that Capan-1 bound less avidly than MIA PaCa-2 ^{25, 26, 28}. Also, when BxPC-3 and PANC-1 were plated on laminin two groups reported that they bound equivalently and two groups reported that BxPC-3 bound more avidly ^{25, 29–31}.

The type of extracellular matrix component utilized is an important variable to consider when comparing and or designing an experiment. For, example when PANC-1 and Capan-1 were plated on a mixture of type I, II, and IV collagen they had close to complete adherence by nine hours, but only roughly 10% and 25% adherence respectively on type II collagen alone at the same time point ²⁴. This experiment also illustrates that the length of time allowed for adherence can alter the outcome. Temporal differences between studies may at least partially explain some of the reported discrepancies, but the pervasive lack of consensus suggests other variables may be important. Cell quantification techniques differ between experimental groups with spectrophotometry and light microscopy being the two most common methodologies. Other variables that could influence experimental outcomes include cell culture conditions and extracellular matrix handling. All of these variables make it difficult to compare the results of different experiments, and individual investigators should verify the differential adhesive properties of the specific cell lines used in a given study.

Cell Migration and Invasion

Just as tumor cell adhesion is a key mediator in the process of metastasis and invasion, cell migration is also an important component in the spread of pancreas cancer⁵. In early stages of the disease, cancer spread is thought to occur after tumor cells infiltrate the peritoneal cavity and gain access to blood vessels³². Thus, the study of the migratory abilities of pancreas cancer cells is necessary to provide insight into the biological processes that mediate metastasis. Several techniques have proven useful for assessing cell migration. With the traditional Boyden chamber, cells migrate in a chemotactic gradient through pores of a filter separating two chambers³³. A modification of this technique using transwell inserts in 24 and 96 well culture plates allows for replicate parallel experiments under identical culture conditions. Another common technique is the wound-healing cell migration assay³⁴, which quantifies the time or distance for cells to repopulate an artificial wound scratched into a near confluent cell culture.

Reports of migration assay data that directly compare two or more PA cell lines are limited. In a transwell migration assay, Stahle and coworkers demonstrated that PANC-1 cells had 5-fold greater motility than BxPC-3 cells³⁵. PANC-1 cells also appeared to migrate predominantly as single cells whereas BxPC-3 cells migrated as a tightly packed sheet in a wound healing assay³⁵. Migration of PANC-1 cells was also greater than BxPC-3 cells on transwell filters coated with collagen 1³⁶. Cell motility can also be assessed by measuring the area of phagokinetic tracks of cells moving through colloid-plated substrates. Using this technique, Lin and colleagues showed that HPAF-II cells had greater motility than BxPC-3 cells³⁷.

Another important phenotype of PA cells is its invasive properties, as pancreas cancer is highly aggressive and invasive by nature, with almost all patients presenting with metastasis at the time of diagnosis. Indeed, the presence of metastases is thought to be responsible for the poor prognosis of this disease³⁸. Over 80% of pancreas cancer patients have tumor extension into the peripancreatic tissues and metastases to local lymph nodes⁵. Invasion is a unique characteristic of malignant cells and is a key step in the series of events which lead to metastasis³⁹. Whereas migration assays monitor cell movement, invasion assays monitor cell movement through a specific matrix, usually measured in transwell filters coated with reconstituted extracellular matrix, with Matrigel (a mixture of laminin, type IV collagen, entactin and heparin sulfate) being the most commonly used extracellular matrix⁴⁰.

The current literature contains a number of studies that have analyzed the invasive propensities of PA cell lines through various substrates (Table 3). There does appear to be agreement that Capan-1 and MIA PaCa-2 cells have similar invasive properties in Matrigel^{25, 27, 41}. In contrast, there are discrepancies when BxPC-3 is compared to MIA PaCa-2. Funahashi⁴² reported that BxPC-3 was more invasive in Matrigel, collagen, and laminin than MIA PaCa-2, however, several other investigators observed similar invasive properties for BxPC-3 and MIA PaCa-2 cells in Matrigel^{25, 39, 43}. Another controversy lies in the relative invasive ability of MIA PaCa-2 and PANC-1 cells. Specifically, Duxbury reported that PANC-1 exhibited more invasion through Matrigel than MIA PaCa-2⁴⁴, but two other groups claimed that MIA PaCa-2 was more invasive than PANC-1^{39, 41}. Some of the above studies utilized commercially available kits for the measurement of invasion^{39, 43, 45, 46}, while others made their own^{25, 27, 37, 41, 42}. Thus, subtle differences in methodology may explain the varied results. Other important variables to consider are cell culture conditions, time, and cell quantification techniques. The variability in invasion properties between experiments again suggests that each investigator characterize their own cell lines when drawing conclusions from differential invasive capabilities.

Angiogenic Potential

Angiogenesis, the process by which cancerous cells induce proliferation of endothelial cells leading to subsequent formation of new blood vessels, is quintessential to tumor growth and metastasis⁴⁷. Tumor microvessel density (MVD) is generally considered a valid predictor of tumor progression and patient survival, predominantly in tumors that induce significant neovascularization such as breast and prostate carcinomas⁴⁸. The prognostic capacity of MVD in PA is ambiguous with some reports indicating a significant correlation^{49, 50} while others showed none^{51–53}. Tumor proliferation is associated with an angiogenic switch in which the presence of pro-angiogenic factors outweigh anti-angiogenic factors^{54–57} and expression of pro-angiogenic factors, particularly vascular endothelial growth factor (VEGF), correlates with MVD in PA^{49, 50, 53}. The aggressiveness of PA may be linked to angiogenesis in that many pro-angiogenic factors over expressed in PA are also mitogenic⁵⁸.

Expression of pro-angiogenic cytokines, chemokines, enzymes and their products have been used to assess the angiogenic potential of PA cell lines. Recent attention has focused on the inducible enzyme cyclooxygenase-2 (COX-2), also known as prostaglandin-endoperoxide synthase 2 (PTGS2), which is over expressed in multiple malignancies, including pancreatic cancer^{59, 60}. One mechanism through which COX-2 promotes angiogenesis is by converting arachidonic acid into bioactive molecules, such as prostaglandin E2 (PGE₂), which act as activating factors in angiogenesis⁶¹. Furthermore, selective COX-2 inhibitors potentiate the growth inhibitory effects of chemotherapeutic agents used in pancreatic cancer treatment^{62, 63}. In addition to their direct stimulatory role in angiogenesis⁶⁴, prostaglandins activate Nuclear Factor- κ B, which in turn up-regulates the expression of COX-2⁶⁵ contributing to angiogenic signal propagation. Expression in PA cell lines of the cytokines IL-1 α and IL-8 have also been used as surrogate markers of angiogenesis. IL-8 has is known to induce proliferation and chemotaxis of vascular endothelial cells^{66–68} and promotes growth of pancreatic tumors⁶⁹.

Although several groups have reported differential COX-2 expression in PA cell lines^{70–73}, very little quantitative information is available. In our laboratory, we used relative quantitation to measure basal COX-2 protein expression in the 11 cell lines (Figure 1, Table 4) by densitometric analysis of Western blots. These data are consistent with qualitative reports that showed that COX-2 protein expression was detectable in BxPC-3, Capan-1, Capan-2 and HPAF-II, but not AsPC-1, MIA PaCa-2 or PANC-1 cell lines^{70–73}. Furthermore, with the exception of Capan-2, the measured expression of COX-2 protein was remarkably similar to the reported differential levels of PGE₂^{74, 75} suggesting that expression corresponds to function of COX-2 in PA cell lines. In our study, Capan-2 showed highly variable COX-2 expression in the four replicate experiments (Figure 1) indicating that COX-2 expression was highly dependent in experimental conditions in this cell line. Capan-2, and PANC-1, also showed variable relative expression of other pro-angiogenic factors (Table 4). However, for those cell lines examined in three or more studies, consensus was achieved for several cell lines. BxPC-3 and Capan-1 both showed consistently high levels of pro-angiogenic factors suggesting a high angiogenic potential for these cell lines, whereas AsPC-1 and MIA PaCa-2 showed consistently low levels of pro-angiogenic factors.

A question remains as to the value of measuring pro-angiogenic factors as a surrogate for angiogenic potential rather than direct measurement of differential angiogenesis in PA cell lines. Although several studies report direct measurement of angiogenesis for individual cell lines, there is a paucity of information directly comparing multiple cell lines. Matsuo et al. showed that BxPC-3 cells secreted high levels of IL-1 α and IL-8 whereas Capan-2 and MIA PaCa-2 cells secreted much lower levels of IL-8 and undetectable levels of IL-1 α ⁷⁶.

Consistent with a role for these cytokines in angiogenesis, tube formation by HUVEC cells was significantly enhanced by co-culture with BxPC-3, but not MIA PaCa-2 cell lines and enhanced tube formation was attenuated in the presence of IL-1 α or IL-8 blocking antibodies ⁷⁶. These data are consistent with the consensus conclusion drawn above, that BxPC-3 and Capan-1 have high pro-angiogenic potential and ASPC-1 and MIA PaCa-2 have low pro-angiogenic potential, and suggest that levels of pro-angiogenic factor may be a useful surrogate for angiogenic potential.

Tumorigenicity

Tumorigenicity describes a cancer cell line's ability or propensity to produce tumors *in vivo*. Tumor volume, tumor mass, frequency to develop and/or rate of growth have been used to estimate tumorigenicity. These parameters have been commonly measured after injecting a suspension of pancreas cancer cells into the subcutaneous tissue of an immunocompromised mouse and allowing a tumor to form. Tumor volume and/or mass are then measured at autopsy. Other methods to determine tumorigenicity include intraperitoneal or intravenous injection of tumor cells, orthotopic transplantation of tumor tissue obtained from a donor nude mouse with a subcutaneous tumor, or direct orthotopic injection of human PA cells into the pancreas of nude mice. Individually, these models recapitulate some, but not all, aspects of the natural course of clinical tumor progression. Furthermore, research has shown that the site of growth influences genetic signaling and thus could be a confounding variable when comparing studies ⁷⁷. Although our review yielded no overall consensus for tumorigenicity in PA cell lines, it is clear that differential tumorigenicity is highly dependent on the specific characteristic measured.

Subcutaneous injections of tumor cells is technically convenient in that the injection site is readily accessible, multiple tumors can be grown in the same mouse, and repeated measurements of tumor size can be easily made lending power to statistical comparisons. Of the few studies that had quantitative measures of tumor size in the subcutaneous injection model, little consensus was apparent (Table 5). In two studies, BxPC-3 tumors were consistently larger than PANC-1 tumors ^{78, 79} whereas a third showed the opposite ⁸⁰. The time for tumor development appears to be a critical factor in the subcutaneous injection model and may contribute to the reported discrepancies in tumor size. Diaz and coworkers ⁸¹ injected mice with suspensions of either BxPC-3, Capan-1 or PANC-1 cells and found that after 14 weeks only the Capan-1-injected mice had developed tumors. It reportedly took more than 4 months for the BxPC-3 and PANC-1 mice to develop tumors. Elevated latency for BxPC-3 tumor development was confirmed in another study in which BxPC-3 tumors did not begin growing until 40 days after injection ⁸². In the same study, Capan-1 tumors had measurable growth increase ten days after injection. Another study showed a 4 week latency for PANC-1 tumor formation and a 3 week latency period for MIA PaCa-2 tumors ⁸³. Taken together, the results of these studies suggest a consensus in which Capan-1 cells rapidly form tumors whereas BxPC-3 and PANC-1 cells have high latency periods before tumor development after subcutaneous injection.

When Severe Combined Immunodeficiency (SCID) mice received intraperitoneal injections of 5×10^6 cells 100% of the Capan-1, 86% of the Panc-1, and 66% of the MIA PaCa-2 developed primary tumors after one week. Thus it appears that Capan-1 can consistently produce subcutaneous and intraperitoneal tumors, but there is variability in the ability of MIA PaCa-2 and Panc-1 to produce tumors. In terms of intraperitoneal tumor size after 30 days the MIA PaCa-2 tumors were the largest. Capan-1 tumors were second largest and PANC-1 produced the smallest tumors ⁸⁴.

An alternative method for determining tumorigenicity parameters involves using donor nude mice to grow tumors, which are then removed, sliced into small fragments and then placed directly into the pancreas of a recipient nude mouse. The subsequent tumors in the recipient mouse are then used to measure tumor volume, tumor mass, or growth rate. Since latency is less of a problem, this method often yields robust tumor growth. Eibl et al.⁸⁵ reported that nude mice that received orthotopic implants of 1 mm³ Capan-2 and MIA PaCa-2 tumor fragments into the tail of the pancreas developed significantly smaller Capan-2 tumors than MIA PaCa-2 tumors. They also report that 100% of the recipient mice developed tumors. In another study, nude mice were subjected to orthotopic transplants of 1mm³ tumor fragments into the tail of the pancreas, and the results showed that tumor volumes were largest for MIA PaCa-2, PANC-1 tumors were second largest, and finally AsPC-1 yielded the smallest tumors⁸⁶. A similar study resulted in HPAF-II tumors that were twice as large as tumors in the AsPC-1 group⁸⁷. Thus it appears that MIA PaCa-2 tumor implants consistently produced larger tumors whereas AsPC-1 tumor implants produced smaller tumors.

Orthotopic implantation of tumor fragments may not fully recapitulate the early events of clinical tumor development since angiogenic signals and tumor microenvironment are established in the subcutaneous setting. Orthotopic injection of tumor cells requires *de novo* tumor development in the context of the pancreas and thus should better mimic the clinical course of the disease. Few studies have been reported that compare multiple cell lines although one comprehensive study in which SCID mice received injections of 10⁶ PA cells directly into the pancreas yielded the following data concerning the percentage of mice that developed tumors after 100 days: AsPC-1: 100% (10/10), CFPAC-1: 100% (10/10), HPAF-II: 100% (8/8), Capan-2: 90% (9/10), Hs 766T: 90% (9/10), HPAC: 88% (7/8), PANC-1: 80% (8/10), and BxPC-3: 67% (6/9)⁸⁸. Katayama et al.⁸⁹ observed that tumor masses were consistently higher for orthotopically injected MIA PaCa-2 than for HPAC cells when measured between 2 and 5 weeks. Another study showed that MIA PaCa-2 and AsPC-1 cells had similar growth characteristics at 2 and 5 weeks post orthotopic injection⁹⁰.

One study of interest compared tumors developed from implanted tumor fragments to tumors developed from direct injection of tumor cells into the pancreas of nude mice⁹¹. Tumors developed in 100% of mice subjected to implantation, however, tumor development varied in mice subjected to orthotopic injection. Specifically, AsPC-1 had 100% tumor development compared to 92% for HPAF-II, 83% for MIA PaCa-2, and 33% for Capan-1. At necropsy (14 weeks) tumor volume was largest to smallest in the following order: HPAF-II > MIA PaCa-2 > AsPC-1 Capan-1 for implanted tumors⁹¹. Tumor volumes showed a similar magnitude and propensity using injected cell lines, although Capan-1 tumors were significantly smaller than seen for implanted tumors⁹¹. This study demonstrates that, at least for some cell lines, tumorigenicity may vary depending on the methodology used.

GENOTYPE

Pancreatic cancers accumulate multiple genetic alterations, including frequent mutations in the KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog), TP53 (encoding the p53 protein), CDKN2A (also known as p16 or p16INK4a), and SMAD4 (SMAD family member 4, also known as DPC4; deleted in pancreatic carcinoma locus 4) genes^{92–94}. A summary of these four mutations in PA cell lines is presented in Table 6. Information on the genotype of these cell lines provide a background for understanding how alterations in these pathways contribute to the growth characteristics, tumorigenicity, and chemosensitivity. The relationship of genotype to phenotype is still unclear, as there are few studies available that directly assess the effect of these mutations on cell behavior. There is some evidence that the mutational status of KRAS, TP53, CDKN2A/p16, and SMAD4/DPC4 do not correlate with either the grade of differentiation⁹⁵ or the biological behavior⁹⁶ of pancreatic cancer cell

lines. However, one group found that *in vivo* metastatic behavior was associated with p53 status, suggesting that genotype and phenotype may be related ⁸⁸.

KRAS mutations are very common in pancreatic cancer, occurring in almost all primary tumors, and are present early in the progression of the disease ^{97–99}. The RAS family members (H-, K- and N-RAS) are guanine nucleotide binding proteins that transmit signals from cell surface receptors by cycling from an inactive GDP-bound state to an active GTP-bound state. Mutations in codons 12, 13, or 61 inhibit the GTPase activity of RAS, leading to oncogenic RAS protein that is constitutively activated in its GTP-bound state, inducing multiple signaling pathways ¹⁰⁰. Of clinical significance are the findings that activating mutations of KRAS activate the Raf/mitogen-activated protein kinase pathway and the Akt/protein kinase B pathway, resulting in the up-regulation of COX-2 transcription and stabilization of its mRNA, respectively ⁶³. Loukopoulos *et al.* directly measured the four most common mutations using sequence analysis in ten pancreatic cancer cell lines ⁸⁸. Mutations were found in the second base of codon 12 of KRAS in all cell lines but two (Hs 766T, BxPC-3) ⁸⁸. In a similar study by Berrozpe and co-workers, KRAS codon 12 mutations were found in 14 of 17 pancreatic cancer cell lines analyzed while Hs 766T, BxPC-3, and SW979 were determined to be wild-type ¹⁰¹. In these and other studies which looked exclusively at exon 1 of KRAS, no mutations were found for Hs 766T. In a subsequent assay assessing the activation state of RAS by measuring the percentage of RAS bound to GTP, Hs 766T was found to contain a high level of activated RAS, similar to cell lines containing a codon 12 mutation. Sequencing of KRAS exon 2 revealed an activating mutation in codon 61 of Hs 766T ¹⁰². There is a consensus that BxPC-3 cells contain wild-type RAS and are not RAS-activated. Consequently, although BxPC-3 is one of the most commonly used PA cell lines, it is probably not representative of the majority of pancreatic cancers.

Inactivation of the CDKN2A/p16 tumor suppressor gene is thought to be an early event in the progression of pancreas cancers, since CDKN2A/p16 inactivation can be found in up to 40% of precursor PanIN (Pancreatic Intraepithelial Neoplasia) lesions ^{103, 104}. The p16 pathway is disrupted, either by mutation, homozygous deletion, or promoter methylation, in up to 98% of all pancreatic carcinomas ¹⁰⁵. In a recent examination of 25 primary ductal adenocarcinomas, p16 was inactivated or mutated in 80% of tumors ¹⁰⁶. The most common cause of p16 inactivation was aberrant promoter methylation, seen in 52% of cases. Sequence mutations (16%) and homozygous deletions (12%) were also found. Correspondingly, p16 is also inactivated in many pancreas cancer cell lines. Using PCR and direct sequencing of exons 1 and 2, Loukopoulos found alterations of CDKN2A/p16 in 7 of 10 cell lines ⁸⁸. Capan-1 and PANC-1 contained homozygous deletions, while HPAF-II had an in-frame deletion and HPAC had a mutation in exon 2. In each case, sequence analysis detected only the mutated allele, indicating a loss of the normal allele which is important for loss of tumor suppressor function. CFPAC-1 contained wild-type sequence but did not express protein, as shown by western blotting. This is in agreement with previous reports that the CDKN2A/p16 promoter is methylated in CFPAC-1 cells ¹⁰⁷. Similarly, BxPC-3 showed a wild-type sequence but undetectable protein product. This may be explained by the presence of a homozygous deletion in exons 2–3 ^{108–110}. AsPC-1, Capan-2 and Hs 766T were reported to be wild-type for the CDKN2A/p16 sequence. However, AsPC-1 has also been shown in other reports to have either a homozygous deletion of CDKN2A/p16 exons 2–3 ¹¹⁰ and/or a frameshift mutation ^{107–109}. Capan-2 does express p16 protein, however this protein was shown by other groups to be inactivated by an insertion in codons 11 and 12 ^{108, 109}. There is also disagreement on the status of Hs 766T, which was shown to be wild-type for CDKN2A/p16 but has also been found to contain possible mutations ^{108, 109}. Considering these discrepancies, it is possible that all of these cell lines are lacking functional CDKN2A/p16. Additionally, taking into account epigenetic changes such as

methylation, CDKN2A/p16 deficiency may be the most common occurrence in the development of pancreas cancer.

Mutations in the TP53 tumor suppressor gene are common in many types of human tumors, including more than 50% of pancreatic adenocarcinomas, where they occur late in the tumorigenesis process⁹⁴. Berrozpe *et al.*¹⁰¹ reported TP53 mutations in 26% of primary pancreas cancers and metastases. Interestingly, mutations were much more common in cell lines, with 15 of 17 pancreatic cancer cell lines showing mutations. Moore found TP53 mutations in 95% of the cell lines tested¹⁰⁷. In the Loukopoulos study, TP53 mutations were missense in eight of ten cell lines, with Capan-2 and HPAC being wild-type⁸⁸. As seen with CDKN2A/p16, only the mutant p53 allele was detected, indicating loss of the wild-type allele. Capan-2 has been reported by several groups to be wild-type for TP53, but it should be noted that Berrozpe found a 200-bp deletion¹⁰¹. In support of Capan-2 possessing wild-type TP53 is a study showing that radiation was able to induce elevated TP53 and p21WAF1/CIP1 protein expression in Capan-2 cells, suggesting the presence of a functional TP53 response. This response to radiation was not seen in PANC-1 or MIA PaCa-2 cells, which contain TP53 mutations¹¹¹. There is also some discrepancy on the TP53 status of Hs 766T, with some groups finding mutations while others report wild-type sequence. In one case, the presence of a mutation was detected between codons 225–282, but the actual mutation was not sequenced¹⁰¹. Overall, mutations in TP53 were very common in PA cell lines. TP53 and CDKN2A/p16 both play significant roles in G1/S cell cycle checkpoint control and maintenance of genome integrity after DNA damage. The high frequency of loss of CDKN2A/p16 and TP53 underscores the importance of abrogation of the G1/S cell cycle checkpoint in the progression of pancreatic cancer.

SMAD4/DPC4, a member of the transforming growth factor β family and also a tumor suppressor, is inactivated in approximately 48 – 55% of invasive pancreatic adenocarcinomas^{112, 113}. Accordingly, SMAD4/DPC4 inactivation has been found at a similar rate in PA cell lines. BxPC-3, CFPAC-1, and Hs 766T have all been shown to lack SMAD4/DPC4 protein due to homozygous deletions^{88, 110, 112, 114, 115}. Capan-1 cells possess a point mutation in SMAD4/DPC4 that result in loss of expression^{88, 113}. However, no SMAD4/DPC4 alterations have been found in Capan-2, MIA PaCa-2, PANC-1, or SU. 86.86^{88, 107, 110}. Divergent results have been seen for AsPC-1, with some groups finding wild-type sequence^{88, 107, 114} while others have reported a non-conservative point mutation¹¹³ or homozygous deletion¹¹⁰. In a comprehensive analysis by Moore, using direct sequencing as well as methylation-specific PCR to test for the four mutations in 22 pancreatic cancer cell lines, inactivation of SMAD4/DPC4 was always found along with alterations in the three other genes¹⁰⁷. This supports data from a study on the molecular pathogenesis of pancreas adenocarcinoma which shows that loss of SMAD4/DPC4 occurs late in the progression towards invasive cancers⁹⁷.

To summarize, there is a consensus that KRAS is activated in 10 of 11 cell lines, with BxPC-3 being the wild-type exception. SMAD4/DPC4 is clearly inactivated in 4 of the 11 cell lines. AsPC-1 was the only cell line with divergent results for SMAD4/DPC4. The status of the tumor suppressor genes TP53 and CDKN2A/p16 are more inconsistent. The three cell lines AsPC-1, Capan-2, and Hs 766T showed variable alterations in these genes. It is possible that these cells have acquired additional alterations during routine culturing. It is also been suggested that heterogeneous populations in the original tumor could provide a source of different genetic variants¹¹⁰. With this in mind, researchers should be aware of the potential for discrepancies in the mutational status of cell lines currently being used in each individual laboratory versus that reported in the literature.

CONCLUSIONS

Sufficient discrepancies exist in the literature for both phenotype and genotype of PA cell lines to warrant careful scrutiny during cell line selection and thorough application of appropriate controls during experimental design. Although some discrepancies might be explained by technical differences in the application of specific assays, it is likely that differential selection of a heterogeneous tumor cell population inherent in the individual cell lines and differential accumulation of genetic changes (“drift”) contribute to the reported disparities. Phenotypic differences due to differential propagation of cell lines have been well documented with long-term sub-culturing resulting in divergent effects on morphology, development, and gene expression^{116–121}. Long-term propagation may introduce selective pressures leading to overgrowth of faster growing or more adherent sub-types. Cross-contamination, mycoplasma contamination, and miss-identification have long plagued the study of cell lines and are also likely contributing factors to the observed discrepancies. These findings suggest that investigators authenticate cell lines and limit the number of passages.

Several points of consensus were identified in our review; however, it is clear that reproduction of prior results may be problematic and investigators should limit interpretations to internally consistent data. Although it may be convenient to consider PA cell lines as representing a homogeneous population of cells, the potential for genetic drift and the presence of tumor cell sub-types suggests that it may be expedient and more reflective of the clinical situation to consider PA cell lines as a heterogeneous population of cells.

Acknowledgments

This work was supported in part by a Ruth L. Kirschstein National Research Service Award from the National Institutes of Health (T35HL07744) to E.L.D.

References

1. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science* 2008;321:1801–1806. [PubMed: 18772397]
2. Douglas EJ, Fiegler H, Rowan A, et al. Array comparative genomic hybridization analysis of colorectal cancer cell lines and primary carcinomas. *Cancer Res* 2004;64:4817–4825. [PubMed: 15256451]
3. Larramendy ML, Lushnikova T, Bjorkqvist AM, et al. Comparative genomic hybridization reveals complex genetic changes in primary breast cancer tumors and their cell lines. *Cancer Genet Cytogenet* 2000;119:132–138. [PubMed: 10867149]
4. Arumugam T, Simeone DM, Van Golen K, et al. S100P promotes pancreatic cancer growth, survival, and invasion. *Clin Cancer Res* 2005;11:5356–5364. [PubMed: 16061848]
5. Marchesi F, Monti P, Leone BE, et al. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. *Cancer Res* 2004;64:8420–8427. [PubMed: 15548713]
6. Arumugam T, Ramachandran V, Fournier KF, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. *Cancer Res* 2009;69:5820–5828. [PubMed: 19584296]
7. Chen WH, Horoszewicz JS, Leong SS, et al. Human pancreatic adenocarcinoma: in vitro and in vivo morphology of a new tumor line established from ascites. *In Vitro* 1982;18:24–34. [PubMed: 7182348]
8. Tan MH, Nowak NJ, Loor R, et al. Characterization of a new primary human pancreatic tumor line. *Cancer Invest* 1986;4:15–23. [PubMed: 3754176]

9. Kyriazis AP, Kyriazis AA, Scarpelli DG, et al. Human pancreatic adenocarcinoma line Capan-1 in tissue culture and the nude mouse: morphologic, biologic, and biochemical characteristics. *Am J Pathol* 1982;106:250–260. [PubMed: 6278935]
10. McIntyre LJ, Kim YS. Effects of sodium butyrate and dimethylsulfoxide on human pancreatic tumor cell lines. *Eur J Cancer Clin Oncol* 1984;20:265–271. [PubMed: 6200329]
11. Kyriazis AA, Kyriazis AP, Sternberg CN, et al. Morphological, biological, biochemical, and karyotypic characteristics of human pancreatic ductal adenocarcinoma Capan-2 in tissue culture and the nude mouse. *Cancer Res* 1986;46:5810–5815. [PubMed: 3019537]
12. Schoumacher RA, Ram J, Iannuzzi MC, et al. A cystic fibrosis pancreatic adenocarcinoma cell line. *Proc Natl Acad Sci U S A* 1990;87:4012–4016. [PubMed: 1692630]
13. McWilliams R, Highsmith WE, Rabe KG, et al. Cystic fibrosis transmembrane regulator gene carrier status is a risk factor for young onset pancreatic adenocarcinoma. *Gut* 2005;54:1661–1662. [PubMed: 16227367]
14. Pezzilli R, Morselli-Labate AM, Mantovani V, et al. Mutations of the CFTR gene in pancreatic disease. *Pancreas* 2003;27:332–336. [PubMed: 14576497]
15. Malats N, Casals T, Porta M, et al. Cystic fibrosis transmembrane regulator (CFTR) DeltaF508 mutation and 5T allele in patients with chronic pancreatitis and exocrine pancreatic cancer. PANKRAS II Study Group. *Gut* 2001;48:70–74. [PubMed: 11115825]
16. Gower WRRR Jr, Godellas CV, Fabri PJ. HPAC, a new human glucocorticoid-sensitive pancreatic ductal adenocarcinoma cell line. *In Vitro Cell Dev Biol* 1994;30A:151–161.
17. Metzgar RS, Gaillard MT, Levine SJ, et al. Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies. *Cancer Res* 1982;42:601–608. [PubMed: 7034925]
18. Owens RB, Smith HS, Nelson-Rees WA, et al. Epithelial cell cultures from normal and cancerous human tissues. *J Natl Cancer Inst* 1976;56:843–849. [PubMed: 176412]
19. Smith HS. In vitro properties of epithelial cell lines established from human carcinomas and nonmalignant tissue. *J Natl Cancer Inst* 1979;62:225–230. [PubMed: 283258]
20. Yunis AA, Arimura GK, Russin DJ. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. *Int J Cancer* 1977;19:218–235.
21. Lieber M, Mazzetta J, Nelson-Rees W, et al. Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. *Int J Cancer* 1975;15:741–747. [PubMed: 1140870]
22. Drucker BJ, Marincola FM, Siao DY, et al. A new human pancreatic carcinoma cell line developed for adoptive immunotherapy studies with lymphokine-activated killer cells in nude mice. *In Vitro Cell Dev Biol* 1988;24:1179–1187. [PubMed: 3264833]
23. McIntyre LJ, Kleinman HK, Martin GR, et al. Attachment of human pancreatic tumor cell lines to collagen in vitro. *Cancer Res* 1981;41:3296–3299. [PubMed: 7260895]
24. Givant-Horwitz V, Davidson B, Reich R. Laminin-induced signaling in tumor cells: the role of the M(r) 67,000 laminin receptor. *Cancer Res* 2004;64:3572–3579. [PubMed: 15150114]
25. Greco E, Basso D, Fogar P, et al. Pancreatic cancer cells invasiveness is mainly affected by interleukin-1beta not by transforming growth factor-beta1. *Int J Biol Markers* 2005;20:235–241. [PubMed: 16398405]
26. Navaglia F, Fogar P, Greco E, et al. CD44v10: an antimetastatic membrane glycoprotein for pancreatic cancer. *Int J Biol Markers* 2003;18:130–138. [PubMed: 12841682]
27. Shirk AJ, Kuver R. Epidermal growth factor mediates detachment from and invasion through collagen I and Matrigel in Capan-1 pancreatic cancer cells. *BMC Gastroenterol* 2005;5:12. [PubMed: 15801978]
28. Stefani AL, Basso D, Panozzo MP, et al. Cytokines modulate MIA PaCa 2 and CAPAN-1 adhesion to extracellular matrix proteins. *Pancreas* 1999;19:362–369. [PubMed: 10547196]
29. Arao S, Masumoto A, Otsuki M. Beta1 integrins play an essential role in adhesion and invasion of pancreatic carcinoma cells. *Pancreas* 2000;20:129–137. [PubMed: 10707927]
30. Sawai H, Yamamoto M, Okada Y, et al. Alteration of integrins by interleukin-1alpha in human pancreatic cancer cells. *Pancreas* 2001;23:399–405. [PubMed: 11668210]

31. Lohr M, Trautmann B, Gottler M, et al. Expression and function of receptors for extracellular matrix proteins in human ductal adenocarcinomas of the pancreas. *Pancreas* 1996;12:248–259. [PubMed: 8830331]
32. Kleeff J, Friess H, Berberat PO, et al. Pancreatic cancer--new aspects of molecular biology research. *Swiss Surg* 2000;6:231–234. [PubMed: 11077487]
33. Boyden S. The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. *J Exp Med* 1962;115:453–466. [PubMed: 13872176]
34. Cai AQ, Landman KA, Hughes BD. Multi-scale modeling of a wound-healing cell migration assay. *J Theor Biol* 2007;245:576–594. [PubMed: 17188306]
35. Stahle M, Veit C, Bachfischer U, et al. Mechanisms in LPA-induced tumor cell migration: critical role of phosphorylated ERK. *J Cell Sci* 2003;116:3835–3846. [PubMed: 12902401]
36. Menke A, Philippi C, Vogelmann R, et al. Down-regulation of E-cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines. *Cancer Res* 2001;61:3508–3517. [PubMed: 11309315]
37. Lin M, DiVito MM, Merajver SD, et al. Regulation of pancreatic cancer cell migration and invasion by RhoC GTPase and caveolin-1. *Mol Cancer* 2005;4:21. [PubMed: 15969750]
38. Farrell TJ, Barbot DJ, Rosato FE. Pancreatic resection combined with intraoperative radiation therapy for pancreatic cancer. *Ann Surg* 1997;226:66–69. [PubMed: 9242339]
39. Takada M, Nakamura Y, Koizumi T, et al. Suppression of human pancreatic carcinoma cell growth and invasion by epigallocatechin-3-gallate. *Pancreas* 2002;25:45–48. [PubMed: 12131770]
40. Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. *Cancer Res* 1987;47:3239–3245. [PubMed: 2438036]
41. Ellenrieder V, Hendler SF, Ruhland C, et al. TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. *Int J Cancer* 2001;93:204–211. [PubMed: 11410867]
42. Funahashi H, Takeyama H, Sawai H, et al. Alteration of integrin expression by glial cell line-derived neurotrophic factor (GDNF) in human pancreatic cancer cells. *Pancreas* 2003;27:190–196. [PubMed: 12883269]
43. Nio Y, Ohmori H, Minari Y, et al. A quinolinone derivative, vesnarinone (OPC-8212), significantly inhibits the in vitro and in vivo growth of human pancreatic cancer cell lines. *Anticancer Drugs* 1997;8:686–695. [PubMed: 9311445]
44. Duxbury MS, Ito H, Zinner MJ, et al. EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. *Oncogene* 2004;23:1448–1456. [PubMed: 14973554]
45. Jimenez RE, Hartwig W, Antoniu BA, et al. Effect of matrix metalloproteinase inhibition on pancreatic cancer invasion and metastasis: an additive strategy for cancer control. *Ann Surg* 2000;231:644–654. [PubMed: 10767785]
46. Okada Y, Takeyama H, Sato M, et al. Experimental implication of celiac ganglionotropic invasion of pancreatic-cancer cells bearing c-ret proto-oncogene with reference to glial-cell-line-derived neurotrophic factor (GDNF). *Int J Cancer* 1999;81:67–73. [PubMed: 10077155]
47. Folkman J. Tumor angiogenesis: therapeutic implications. *N Engl J Med* 1971;285:1182–1186. [PubMed: 4938153]
48. Sharma S, Sharma MC, Sarkar C. Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis. *Histopathology* 2005;46:481–489. [PubMed: 15842629]
49. Ikeda N, Adachi M, Taki T, et al. Prognostic significance of angiogenesis in human pancreatic cancer. *Br J Cancer* 1999;79:1553–1563. [PubMed: 10188906]
50. Seo Y, Baba H, Fukuda T, et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. *Cancer* 2000;88:2239–2245. [PubMed: 10820344]
51. Ellis LM, Takahashi Y, Fenoglio CJ, et al. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. *Eur J Cancer* 1998;34:337–340. [PubMed: 9640218]

52. Fujimoto K, Hosotani R, Wada M, et al. Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. *Eur J Cancer* 1998;34:1439–1447. [PubMed: 9849429]
53. Itakura J, Ishiwata T, Friess H, et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. *Clin Cancer Res* 1997;3:1309–1316. [PubMed: 9815813]
54. Fang J, Yan L, Shing Y, et al. HIF-1 α -mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. *Cancer Res* 2001;61:5731–5735. [PubMed: 11479208]
55. Giordano FJ, Johnson RS. Angiogenesis: the role of the microenvironment in flipping the switch. *Curr Opin Genet Dev* 2001;11:35–40. [PubMed: 11163148]
56. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *Cell* 1996;86:353–364. [PubMed: 8756718]
57. Udagawa T, Fernandez A, Achilles EG, et al. Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. *Faseb J* 2002;16:1361–1370. [PubMed: 12205027]
58. Korc M. Pathways for aberrant angiogenesis in pancreatic cancer. *Mol Cancer* 2003;2:8. [PubMed: 12556241]
59. Chu J, Lloyd FL, Trifan OC, et al. Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. *Mol Cancer Ther* 2003;2:1–7. [PubMed: 12533667]
60. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. *Proc Natl Acad Sci U S A* 1997;94:3336–3340. [PubMed: 9096394]
61. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. *Cancer Res* 2000;60:1306–1311. [PubMed: 10728691]
62. Ding XZ, Hennig R, Adrian TE. Lipoxigenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer. *Mol Cancer* 2003;2:10. [PubMed: 12575899]
63. El-Rayes BF, Ali S, Sarkar FH, et al. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. *Mol Cancer Ther* 2004;3:1421–1426. [PubMed: 15542781]
64. Form DM, Auerbach R. PGE₂ and angiogenesis. *Proc Soc Exp Biol Med* 1983;172:214–218. [PubMed: 6572402]
65. Poligone B, Baldwin AS. Positive and negative regulation of NF- κ B by COX-2: roles of different prostaglandins. *J Biol Chem* 2001;276:38658–38664. [PubMed: 11509575]
66. Arenberg DA, Kunkel SL, Polverini PJ, et al. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. *J Clin Invest* 1996;97:2792–2802. [PubMed: 8675690]
67. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. *Science* 1992;258:1798–1801. [PubMed: 1281554]
68. Miller LJ, Kurtzman SH, Wang Y, et al. Expression of interleukin-8 receptors on tumor cells and vascular endothelial cells in human breast cancer tissue. *Anticancer Res* 1998;18:77–81. [PubMed: 9568059]
69. Trevino JG, Summy JM, Gray MJ, et al. Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. *Cancer Res* 2005;65:7214–7222. [PubMed: 16103072]
70. Eibl G, Bruemmer D, Okada Y, et al. PGE₂ is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. *Biochem Biophys Res Commun* 2003;306:887–897. [PubMed: 12821125]
71. Eibl G, Reber HA, Wente MN, et al. The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2. *Pancreas* 2003;26:33–41. [PubMed: 12499915]
72. Molina MA, Sitja-Arnau M, Lemoine MG, et al. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. *Cancer Res* 1999;59:4356–4362. [PubMed: 10485483]

73. Yip-Schneider MT, Sweeney CJ, Jung SH, et al. Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. *J Pharmacol Exp Ther* 2001;298:976–985. [PubMed: 11504793]
74. Raut CP, Nawrocki S, Lashinger LM, et al. Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. *Cancer Biol Ther* 2004;3:1217–1224. [PubMed: 15477758]
75. Yip-Schneider MT, Barnard DS, Billings SD, et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. *Carcinogenesis* 2000;21:139–146. [PubMed: 10657949]
76. Matsuo Y, Sawai H, Funahashi H, et al. Enhanced angiogenesis due to inflammatory cytokines from pancreatic cancer cell lines and relation to metastatic potential. *Pancreas* 2004;28:344–352. [PubMed: 15084984]
77. Nakamura T, Fidler IJ, Coombes KR. Gene expression profile of metastatic human pancreatic cancer cells depends on the organ microenvironment. *Cancer Res* 2007;67:139–148. [PubMed: 17210693]
78. Aubert M, Crotte C, Bernard JP, et al. Decrease of human pancreatic cancer cell tumorigenicity by alpha1,3galactosyltransferase gene transfer. *Int J Cancer* 2003;107:910–918. [PubMed: 14601050]
79. Miknyoczki SJ, Chang H, Klein-Szanto A, et al. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma. *Clin Cancer Res* 1999;5:2205–2212. [PubMed: 10473107]
80. Fukasawa M, Korc M. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. *Clin Cancer Res* 2004;10:3327–3332. [PubMed: 15161686]
81. Diaz VM, Planaguma J, Thomson TM, et al. Tissue plasminogen activator is required for the growth, invasion, and angiogenesis of pancreatic tumor cells. *Gastroenterology* 2002;122:806–819. [PubMed: 11875015]
82. Delesque N, Buscail L, Esteve JP, et al. sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. *Cancer Res* 1997;57:956–962. [PubMed: 9041201]
83. Freeman JW, Mattingly CA, Strodel WE. Increased tumorigenicity in the human pancreatic cell line MIA PaCa-2 is associated with an aberrant regulation of an IGF-1 autocrine loop and lack of expression of the TGF-beta type RII receptor. *J Cell Physiol* 1995;165:155–163. [PubMed: 7559796]
84. Fogar P, Greco E, Basso D, et al. Suicide gene therapy with HSV-TK in pancreatic cancer has no effect in vivo in a mouse model. *Eur J Surg Oncol* 2003;29:721–730. [PubMed: 14602490]
85. Eibl G, Reber HA. A xenograft nude mouse model for perineural invasion and recurrence in pancreatic cancer. *Pancreas* 2005;31:258–262. [PubMed: 16163058]
86. Bhargava S, Stummeyer T, Hotz B, et al. Selective inhibition of endothelin receptor A as an anti-angiogenic and anti-proliferative strategy for human pancreatic cancer. *J Gastrointest Surg* 2005;9:703–709. [PubMed: 15862267]
87. Hotz HG, Hines OJ, Masood R, et al. VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. *Surgery* 2005;137:192–199. [PubMed: 15674201]
88. Loukopoulou P, Kanetaka K, Takamura M, et al. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. *Pancreas* 2004;29:193–203. [PubMed: 15367885]
89. Katayama M, Sanzen N, Funakoshi A, et al. Laminin gamma2-chain fragment in the circulation: a prognostic indicator of epithelial tumor invasion. *Cancer Res* 2003;63:222–229. [PubMed: 12517801]
90. Torgenson MJ, Shea JE, Firpo MA, et al. Natural History of Pancreatic Cancer Recurrence Following “Curative” Resection in Athymic Mice. *J Surg Res*. 2007
91. Hotz HG, Reber HA, Hotz B, et al. An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer. *Pancreas* 2003;26:e89–98. [PubMed: 12717279]
92. Cowgill SM, Muscarella P. The genetics of pancreatic cancer. *Am J Surg* 2003;186:279–286. [PubMed: 12946833]

93. Schneider G, Schmid RM. Genetic alterations in pancreatic carcinoma. *Mol Cancer* 2003;2:15. [PubMed: 12605716]
94. Moore PS, Beghelli S, Zamboni G, et al. Genetic abnormalities in pancreatic cancer. *Mol Cancer* 2003;2:7. [PubMed: 12537585]
95. Sipos B, Moser S, Kalthoff H, et al. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. *Virchows Arch* 2003;442:444–452. [PubMed: 12692724]
96. Monti P, Marchesi F, Reni M, et al. A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. *Virchows Arch* 2004;445:236–247. [PubMed: 15258755]
97. Maitra A, Adsay NV, Argani P, et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. *Mod Pathol* 2003;16:902–912. [PubMed: 13679454]
98. Mahlamaki EH, Kauraniemi P, Monni O, et al. High-resolution genomic and expression profiling reveals 105 putative amplification target genes in pancreatic cancer. *Neoplasia* 2004;6:432–439. [PubMed: 15548351]
99. Luttgies J, Reinecke-Luthge A, Mollmann B, et al. Duct changes and K-ras mutations in the disease-free pancreas: analysis of type, age relation and spatial distribution. *Virchows Arch* 1999;435:461–468. [PubMed: 10592048]
100. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. *Nat Rev Cancer* 2003;3:459–465. [PubMed: 12778136]
101. Berrozpe G, Schaeffer J, Peinado MA, et al. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. *Int J Cancer* 1994;58:185–191. [PubMed: 8026879]
102. Yip-Schneider MT, Lin A, Barnard D, et al. Lack of elevated MAP kinase (Erk) activity in pancreatic carcinomas despite oncogenic K-ras expression. *Int J Oncol* 1999;15:271–279. [PubMed: 10402237]
103. Fukushima N, Sato N, Ueki T, et al. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. *Am J Pathol* 2002;160:1573–1581. [PubMed: 12000709]
104. Gerdes B, Ramaswamy A, Kersting M, et al. p16(INK4a) alterations in chronic pancreatitis-indicator for high-risk lesions for pancreatic cancer. *Surgery* 2001;129:490–497. [PubMed: 11283541]
105. Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. *Cancer Res* 1997;57:3126–3130. [PubMed: 9242437]
106. Attri J, Srinivasan R, Majumdar S, et al. Alterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma. *BMC Gastroenterol* 2005;5:22. [PubMed: 15985168]
107. Moore PS, Sipos B, Orlandini S, et al. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. *Virchows Arch* 2001;439:798–802. [PubMed: 11787853]
108. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. *Nat Genet* 1994;8:27–32. [PubMed: 7726912]
109. Huang L, Goodrow TL, Zhang SY, et al. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. *Cancer Res* 1996;56:1137–1141. [PubMed: 8640773]
110. Sun C, Yamato T, Furukawa T, et al. Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. *Oncol Rep* 2001;8:89–92. [PubMed: 11115575]
111. Mohiuddin M, Chendil D, Dey S, et al. Influence of p53 status on radiation and 5-fluorouracil synergy in pancreatic cancer cells. *Anticancer Res* 2002;22:825–830. [PubMed: 12014658]
112. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. *Science* 1996;271:350–353. [PubMed: 8553070]

113. Schutte M, Hruban RH, Hedrick L, et al. DPC4 gene in various tumor types. *Cancer Res* 1996;56:2527–2530. [PubMed: 8653691]
114. Aoki Y, Hosaka S, Tachibana N, et al. Reassessment of K-ras mutations at codon 12 by direct PCR and sequencing from tissue microdissection in human pancreatic adenocarcinomas. *Pancreas* 2000;21:152–157. [PubMed: 10975709]
115. Chen WB, Lenschow W, Tiede K, et al. Smad4/DPC4-dependent regulation of biglycan gene expression by transforming growth factor-beta in pancreatic tumor cells. *J Biol Chem* 2002;277:36118–36128. [PubMed: 12140283]
116. Briske-Anderson MJ, Finley JW, Newman SM. The influence of culture time and passage number on the morphological and physiological development of Caco-2 cells. *Proc Soc Exp Biol Med* 1997;214:248–257. [PubMed: 9083258]
117. Chang-Liu CM, Woloschak GE. Effect of passage number on cellular response to DNA-damaging agents: cell survival and gene expression. *Cancer Lett* 1997;113:77–86. [PubMed: 9065805]
118. Esquenet M, Swinnen JV, Heyns W, et al. LNCaP prostatic adenocarcinoma cells derived from low and high passage numbers display divergent responses not only to androgens but also to retinoids. *J Steroid Biochem Mol Biol* 1997;62:391–399. [PubMed: 9449242]
119. Langelier EG, van Uffelen CJ, Blankenstein MA, et al. Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP. *Prostate* 1993;23:213–223. [PubMed: 7694266]
120. Sambuy Y, De Angelis I, Ranaldi G, et al. The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. *Cell Biol Toxicol* 2005;21:1–26. [PubMed: 15868485]
121. Yu H, Cook TJ, Sinko PJ. Evidence for diminished functional expression of intestinal transporters in Caco-2 cell monolayers at high passages. *Pharm Res* 1997;14:757–762. [PubMed: 9210193]
122. Sawai H, Okada Y, Funahashi H, et al. Activation of focal adhesion kinase enhances the adhesion and invasion of pancreatic cancer cells via extracellular signal-regulated kinase-1/2 signaling pathway activation. *Mol Cancer* 2005;4:37. [PubMed: 16209712]
123. Luo J, Guo P, Matsuda K, et al. Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. *Int J Cancer* 2001;92:361–369. [PubMed: 11291072]
124. Holloway SE, Beck AW, Shivakumar L, et al. Selective Blockade of Vascular Endothelial Growth Factor Receptor 2 With an Antibody Against Tumor-Derived Vascular Endothelial Growth Factor Controls the Growth of Human Pancreatic Adenocarcinoma Xenografts. *Ann Surg Oncol*. 2006
125. Blanchard JA 2nd, Barve S, Joshi-Barve S, et al. Antioxidants inhibit cytokine production and suppress NF-kappaB activation in CAPAN-1 and CAPAN-2 cell lines. *Dig Dis Sci* 2001;46:2768–2772. [PubMed: 11768272]
126. Tong WG, Ding XZ, Hennig R, et al. Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. *Clin Cancer Res* 2002;8:3232–3242. [PubMed: 12374694]
127. Butz J, Wickstrom E, Edwards J. Characterization of mutations and loss of heterozygosity of p53 and K-ras2 in pancreatic cancer cell lines by immobilized polymerase chain reaction. *BMC Biotechnol* 2003;3, 11. [PubMed: 12659646]
128. Kita K, Saito S, Morioka CY, et al. Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes. *Int J Cancer* 1999;80:553–558. [PubMed: 9935156]

Figure 1.

Relative expression of COX-2 in PA cell lines. Basal expression of COX-2 was determined by Western blot analysis in PA cell line lysates and quantified by densitometry. A: Representative Western blot. All cell lines were acquired from the American Type Culture Collection (ATCC, Manassas, VA) and propagated in ATCC recommended media. Cells were grown to 80% confluence before preparation of cell lysates. Proteins were separated by SDS-polyacrylamide gel electrophoresis and transferred to PVDF membranes using standard protocols. The membranes were probed with antibodies to COX-2 (mouse monoclonal, Cayman Chemical, Ann Arbor, MI) and β -actin (rabbit monoclonal, Cell Signaling Technology, Danvers, MA) or GAPDH (mouse monoclonal, Novus Biologicals, Littleton, CO) as total protein loading controls. B: Densitometric analyses. Autoradiographs of Western blots were quantified using ImageJ software (National Institutes of Health, <http://rsb.info.nih.gov/ij/>). COX-2 intensity was first normalized to the corresponding loading control (β -actin or GAPDH) and then normalized to the BxPC-3 ratio for each blot. Data represents the combined results of four independent experiments (mean $\pm$ SEM).

Table 1

Donor patient information and cell line characteristics.

Cell Line	Age	Gender	Derivation ^a	Metastasis	Proliferation ^b	Differentiation	Ref.
AsPC-1	62	Female	Ascites	Yes	38–40 hrs	Poor	7
BxPC-3	61	Female	Primary tumor	No	48–60 hrs	Moderate to poor	8
Capan-1	40	Male	Liver metastasis	Yes	nd ^c	Well	9
Capan-2	56	Male	Primary tumor	No	96 hrs	Well	11
CFPAC-1	26	Male	Liver metastasis	Yes	31 hrs	Well	12
HPAC	64	Female	Primary tumor	nd ^c	41 hrs	Moderate	16
HPAF-II	44	Male	Ascites	Yes	42 hrs	Well	17
Hs 766T	46	Male	Lymph node metastasis	Yes	6–7 days	nd ^c	19
MIA PaCa-2	65	Male	Primary tumor	nd ^c	40 hrs	Poor	20
PANC-1	56	Female	Primary tumor	Yes	52 hrs	Poor	21
SU.86.86	57	Female	Liver metastasis	Yes	77 hrs	Moderate to poor	22

^aHistology for Hs 766T and MIA PaCa-2 were described as “carcinoma”. All other tumors were described as “adenocarcinoma”

^bdoubling time of cell line

^cnot described

Table 2

Comparison of the adhesive ability of pancreas cancer cell lines to various extra cellular matrix proteins.

Substrate	Relative Affinity	Ref.
Collagen I		
	Capan-1 > PANC-1 > MIA PaCa-2	10
	AsPC-1 > BxPC-3 = PANC-1 > MIA PaCa-2	30
	Capan-1 > MIA PaCa-2	27
	Capan-1 > PANC-1, MIA PaCa-2 = 0	26
	Capan-1 > MIA PaCa-2	28
	PANC-1 = BxPC-3 > SU.86.86 > AsPC-1	29
	Capan-1 = BxPC-3 = PANC-1 >> MIA PaCa-2	25
Collagen IV		
	PANC-1 > Capan-1 > MIA PaCa-2	10
	AsPC-1 > PANC-1 > MIA PaCa-2 > BxPC-3	30
	AsPC-1 > BxPC-3 > Capan-2	122
Fibronectin		
	PANC-1 > BxPC-3 > AsPC-1 > SU.86.86	29
	BxPC-3 = MIA PaCa-2 > AsPC-1 = PANC-1	30
	BxPC-3 > PANC-1	31
	MIA PaCa-2 = Capan-1 = PANC-1	26
	MIA PaCa-2 = Capan-1	28
	Capan-1 = BxPC-3 = PANC-1 > MIA PaCa-2	25
Laminin		
	BxPC-3 = PANC-1 > SU.86.86 > AsPC-1	29
	AsPC-1 > BxPC-3 = MIA PaCa-2 = PANC-1	30
	BxPC-3 > PANC-1	31
	Capan-1 = MIA PaCa-2 = PANC-1	26
	Capan-1 > MIA PaCa-2	28
	BxPC-3 > Capan-1 = MIA PaCa-2 = PANC-1	25

Table 3

Comparison of invasive abilities of PA cell lines. Data abstraction was limited to those studies that directly compared multiple cell lines. Measured invasiveness is given in parentheses (mean invaded cells per high-powered field, unless otherwise noted) after each cell line.

Substrate	Relative Effect	Time (Hrs)	Ref.
Matrigel	BxPC-3 (41 ± 4.2) > MIA PaCa-2 (14.7 ± 3.7)	24	42
	BxPC-3 (73.3) = MIA PaCa-2 (90.3)	24	43
	BxPC-3 (~45) = MIA PaCa-2 (~47) = PANC-1 (~40)	12	39
	HPAF-II (~310) ^a > BxPC-3 (~25)	24	37
	Capan-1 (~420) = MIA PaCa-2 (~480) ^b > PANC-1 (~310)	48	41
	Capan-1 (~35) ^c = MIA PaCa-2 (~32)	48	27
	Capan-1 (~190) > AsPC-1 (~95)	96	45
	Capan-2 (44.3 ± 4.3) > AsPC-1 (23.3 ± 5)	24	46
	BxPC-3 (~6) = Capan-1 (~6.5) = MIA PaCa-2 (~11) = PANC-1 (~8)	48 ^d	25
Fibronectin			
	BxPC-3 (42.7 ± 2.2) > MIA PaCa-2 (24 ± 2.9)	24	42
Collagen IV			
	BxPC-3 (~25) > AsPC-1 (~20) = Capan-2 (~17)	24	122
Laminin			
	BxPC-3 (66.7 ± 11.9) > MIA PaCa-2 (7.3 ± 0.7)	24	42

^a cells/chamber

^b cells/cm²

^c % of added cells

^d After 48 hrs, the number cells that had completely migrated into the bottom chamber was significantly higher for Capan-1 and MIA PaCa-2 than for BxPC-3 and PANC-1 cell lines.

Quantitative measurements of pro-angiogenic factors in pancreatic cancer cell lines. The quantitative measurement in the specified units is reported after each cell line (parentheses). Data abstraction was limited to those studies that directly compared multiple cell lines.

Table 4

Factor	Relative Effect	Units	Ref.
COX-2	Capan-2 (200) > SU 86.86 (102) > BxPC-3 (94)> CFPAC-1 (87) > Capan-1 (61) > Hs 766T (26) > HPAC (23) > HPAF-II (7) > MIA PaCa-2 (3) > PANC-1 (3) > AsPC-1 (1)	Relative Intensity	This Study
PGE ₂	BxPC-3 (92.3) > CFPAC-1 (26.2) > MIA PaCa-2 (undetectable)	pg/ml	74
VEGF	BxPC-3 (48) > Capan-1 (18) = Capan-2 (18) > HPAF-II (15) > Hs 766T (3) > AsPC-1 (2) > PANC-1 (1)	pg/μg protein	75
	BxPC-3 (2000) > AsPC-1 (250)	pg/mg protein	59
	HPAF-II (8120) > AsPC-1 (4200)	pg/10 ⁶ cells	87
	BxPC-3 (2383) > PANC-1 (1415) > Capan-1 (981) > MIA PaCa-2 (453) > AsPC-1 (179)	pg/10 ⁶ cells	123
IL-8	Capan-1 (1900) > PANC-1 (1700) > MIA PaCa-2 (850)	pg/ml	124
	BxPC-3 (3.4) > MIA PaCa-2 (0.5) > Capan-2 (0.4)	ng/ml/10 ⁶ cells	76
	Capan-1 (1700) > Capan-2 (220)	pg/ml	125

Table 5

Differential tumorigenicity of PA cell lines. In all experiments, mice received subcutaneous injections of PA cell lines. The reported tumor volume measurement (mm^3) is given in parentheses after each cell line.

# Cells Injected	Relative Effect (Tumor Size, mm^3)	Time (Days)	Ref.
1×10^6	BxPC-3 (~2000) > PANC-1 (~500)	54	78
1×10^6	PANC-1 (~570) > BxPC-3 (~155)	42	80
1×10^6	BxPC-3 (~2000) > AsPC-1 (~1450) > PANC-1 (~750) > MIA PaCa-2 (~525)	21	79
3×10^6	AsPC-1 (~2250) > HPAC (~1300)	24	126

Table 6

Genotype. The four most common mutations in pancreas cancer.

Cell Line	KRAS ^a	TP53	CDKN2A/p16	SMAD4/DPC4
AsPC-1	12 Asp ⁸⁸ , 101, 107, 110, 114, 127, 128	135 Δ1 bp ⁸⁸ , 101, 107, 108 Intron 4 Δ200 bp splice site ¹⁰¹ HD exon 5 ¹¹⁰	WT ⁸⁸ Δ2 bp ^{107–109} HD ¹¹⁰	WT ⁸⁸ , 107, 114 HD ¹¹⁰ 100Thr ¹¹³
BxPC-3	WT ⁸⁸ , 101, 110, 114	220 Cys ⁸⁸ , 101, 108, 110	WT ^{88b} HD ^{108–110}	HD ⁸⁸ , 110, 112, 114
Capan-1	12 Val ⁸⁸ , 101, 127, 128	159 Val ⁸⁸ , 101, 108	HD ⁸⁸ , 108, 109	577 Leu ⁸⁸ 343 STOP ¹¹³
Capan-2	12 Val ⁸⁸ , 101, 114	WT ⁸⁸ , 108 Intron 4 Δ200 bp splice site ¹⁰¹	WT ⁸⁸ 6 bp ins ¹⁰⁸ 7 bp ins ¹⁰⁹	WT ⁸⁸
CFPAC-1	12 Val ⁸⁸ , 107	242 Arg ⁸⁸ , 107, 108	WT ¹⁰⁸ , 109 WT ^{88b} Promoter methylation ¹⁰⁷	HD ⁸⁸ , 107, 112
HPAC	12 Asp ⁸⁸	WT ⁸⁸	112 amber STOP ⁸⁸	WT ⁸⁸
HPAF-II	12 Asp ⁸⁸ , 101, 107	151 Ser ⁸⁸ , 101, 107	Δ20–25 ⁸⁸ Δ26–27 ¹⁰⁹ Δ29–34 ¹⁰⁷	WT ⁸⁸ , 101, 107
Hs 766T	WT ⁸⁸ , 101, 114 61 His ^{102d}	WT ⁸⁸ , 108 Mut 225–282 ^{101c} Δexons 2–4 ^e	WT ⁸⁸ Intron 2 splice site ¹⁰⁸ , 109	HD ⁸⁸ , 112, 114
MIA PaCa-2	12 Cys ¹⁰¹ , 107, 110, 128	248 Trp ¹⁰¹ , 107, 108, 110	HD ^{107–110}	WT ¹⁰⁷ , 110
PANC-1	12 Asp ⁸⁸ , 101, 107, 110, 127, 128	273 His ⁸⁸ , 107, 108, 110, 127 273 Cys ¹⁰¹	HD ⁸⁸ , 107–110	WT ⁸⁸ , 107, 110
SU.86.86	12 Asp ¹¹⁰	245 Ser ¹⁰⁸ , 110	HD ^{108–110}	WT ¹¹⁰

^aKRAS exon 1 sequenced, unless otherwise noted^bWild type sequence, but western blotting product absent^cMutation found between codons 225–282, but not further characterized^dKRAS exons 1 and 2 sequenced^e<http://pathology2.jhu.edu/pancreas/geneticsweb/profiles.htm>

WT—wild type, Δ—deletion, ins—insertion, bp—base pair, HD—homozygous deletion